论文部分内容阅读
目的:探讨化疗联合唑来膦酸对肺癌患者骨转移的疗效及炎性因子的影响。方法:回顾性选择我院2010年1月至2015年12月收治的84例肺癌骨转移患者,根据随机数字表法结合患者意愿,将所有患者平均分为观察组与对照组,每组42例。对照组给予TP方案化疗2个疗程,观察组在对照组基础上给予唑来膦酸治疗2个疗程,观察两组患者治疗后的镇痛效果、活动能力、骨转移灶效果、不良反应及治疗前后的IL-6、TNF-α水平。结果:观察组镇痛效果、活动能力、骨转移灶效果明显高于对照组(P<0.05),观察组与对照组不良反应无统计学意义(P>0.05),与治疗前相比,治疗后两组患者的IL-6、TNF-α水平明显降低,与对照组相比,治疗后治疗组的IL-6、TNF-α水平明显较低(P<0.05)。结论:化疗联合唑来膦酸治疗肺癌骨转移安全有效,可降低炎性因子的释放,增强镇痛效果和活动能力,减缓骨转移。
Objective: To investigate the effect of chemotherapy combined with zoledronic acid on bone metastasis and inflammatory factors in patients with lung cancer. Methods: Eighty-four patients with bone metastasis of lung cancer who were admitted to our hospital from January 2010 to December 2015 were retrospectively selected. All patients were equally divided into observation group and control group according to the random number table method and 42 patients . The control group was given TP chemotherapy two courses, the observation group on the basis of the control group to give zoledronic acid for two courses of treatment to observe the two groups of patients after treatment analgesic effect, activity, bone metastases, adverse reactions and treatment Before and after the IL-6, TNF-α levels. Results: The analgesic effect, mobility and bone metastases in the observation group were significantly higher than those in the control group (P <0.05). There was no significant difference between the observation group and the control group (P> 0.05) The levels of IL-6 and TNF-α in the latter two groups were significantly decreased. Compared with the control group, the levels of IL-6 and TNF-α in the treatment group were significantly lower (P <0.05). Conclusion: Chemotherapy combined with zoledronic acid is safe and effective in the treatment of bone metastasis of lung cancer, which can reduce the release of inflammatory factors, enhance the analgesic effect and activity, and reduce the bone metastasis.